Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Binh Dinh Pharmaceutical And Medical Equipment JSC Debt-to-EBITDA Related Terms
Binh Dinh Pharmaceutical And Medical Equipment JSC Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Binh Dinh Pharmaceutical And Medical Equipment JSC Debt-to-EBITDA Chart
Binh Dinh Pharmaceutical And Medical Equipment JSC Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Binh Dinh Pharmaceutical And Medical Equipment JSC's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Binh Dinh Pharmaceutical And Medical Equipment JSC Debt-to-EBITDA vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Binh Dinh Pharmaceutical And Medical Equipment JSC (STC:DBD) has a Debt-to-EBITDA of 0.64 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Binh Dinh Pharmaceutical And Medical Equipment JSC. This is 78% above median its historical median of 0.36. Over the past decade, Binh Dinh Pharmaceutical And Medical Equipment JSC's Debt-to-EBITDA has ranged from 0.17 to 1.14. According to the industry distribution chart, Binh Dinh Pharmaceutical And Medical Equipment JSC ranks #209 out of 690 companies in the Drug Manufacturers industry, placing it in the top 30.3%.
Is Binh Dinh Pharmaceutical And Medical Equipment JSC's Debt-to-EBITDA too high?
Binh Dinh Pharmaceutical And Medical Equipment JSC's current Debt-to-EBITDA of 0.64 is 78% above median its 10-year median of 0.36. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 1.14. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Binh Dinh Pharmaceutical And Medical Equipment JSC's value of 0.64 is 61.9% below this industry median. Based on the distribution chart, Binh Dinh Pharmaceutical And Medical Equipment JSC ranks #209 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Binh Dinh Pharmaceutical And Medical Equipment JSC has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Binh Dinh Pharmaceutical And Medical Equipment JSC's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Binh Dinh Pharmaceutical And Medical Equipment JSC ranks #209 out of 690 companies for Debt-to-EBITDA. This puts Binh Dinh Pharmaceutical And Medical Equipment JSC in the upper half of its industry. The industry median Debt-to-EBITDA is 1.68. Binh Dinh Pharmaceutical And Medical Equipment JSC's value of 0.64 is 61.9% below this benchmark. Historically, Binh Dinh Pharmaceutical And Medical Equipment JSC's own Debt-to-EBITDA has ranged from 0.17 to 1.14 over the past decade. While the company's 10-year median is 0.36 vs. the industry median of 1.68, Binh Dinh Pharmaceutical And Medical Equipment JSC has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Binh Dinh Pharmaceutical And Medical Equipment JSC's current Debt-to-EBITDA of 0.64 is 61.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Binh Dinh Pharmaceutical And Medical Equipment JSC. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Binh Dinh Pharmaceutical And Medical Equipment JSC's current Debt-to-EBITDA is 0.64, which is 78% above median its own 10-year median of 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Binh Dinh Pharmaceutical And Medical Equipment JSC stock overvalued right now?
Based on GuruFocus' analysis, Binh Dinh Pharmaceutical And Medical Equipment JSC (STC:DBD) is currently considered Fairly Valued. The stock's GF Value™ is ₫52,463.98, compared to a current price of ₫50,900.00 — trading 3% below its estimated fair value. The current Debt-to-EBITDA is 0.64, which is 78% above median its 10-year median of 0.36 and 61.9% below the Drug Manufacturers industry median of 1.68. Binh Dinh Pharmaceutical And Medical Equipment JSC's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Binh Dinh Pharmaceutical And Medical Equipment JSC (STC:DBD), the current Debt-to-EBITDA is 0.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Binh Dinh Pharmaceutical And Medical Equipment JSC (STC:DBD) Overvalued in 2026?
Based on GuruFocus' analysis, Binh Dinh Pharmaceutical And Medical Equipment JSC stock appears to be undervalued.
The current stock price of ₫50,900.00 is trading 3% below its estimated GF Value™ of ₫52,463.98.
GuruFocus considers Binh Dinh Pharmaceutical And Medical Equipment JSC to be Fairly Valued.
Key valuation signals for STC:DBD:
Debt-to-EBITDA: 0.64 (78% above median its 10-year median of 0.36)
GF Value™: ₫52,463.98 vs. price of ₫50,900.00 (3% below fair value)
Industry Position: 61.9% below the Drug Manufacturers median (#209 of 690)
No single metric tells the full story. See the STC:DBD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Binh Dinh Pharmaceutical And Medical Equipment JSC Business Description
Binh Dinh Pharmaceutical And Medical Equipment JSC is a pharmaceutical company. The company is engaged in production and trade of pharmaceutical products, medicinal herbs, pharmaceutical and medical equipment.
82GF Score
Get the complete analysis for STC:DBD
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DBD has been successfully added to your 
